Archives
-
One-step TUNEL Cy3 Apoptosis Detection
2026-09-13
The One-step TUNEL Cy3 Apoptosis Detection Kit provides a precise DNA fragmentation assay for connecting mitochondrial stress biology with apoptotic outcomes in glioblastoma models. This guide explains how to interpret TUNEL signals, design controls, and distinguish downstream DNA cleavage from upstream mitochondrial mechanisms.
-
Vernakalant for Recent-Onset AF Cardioversion
2026-09-12
This post hoc analysis of ACT I and ACT IV evaluated intravenous vernakalant for adults with recent-onset atrial fibrillation lasting more than 3 and up to 48 hours. Vernakalant converted 59.4% of treated patients within 90 minutes versus 4.9% with placebo, with a median conversion time of 12 minutes and no observed torsade de pointes or ventricular fibrillation.
-
FTSJ3 Loss, R-Loops, and Lung Cancer Chemosensitivity
2026-09-11
The reference study identifies FTSJ3 as a regulator of R-loop homeostasis that limits genomic damage in lung cancer cells. Its depletion increases R-loop-associated DNA damage and enhances cisplatin sensitivity in cellular and animal models, supporting FTSJ3 as a potential biomarker and therapeutic vulnerability rather than an immediately validated clinical target.
-
Forsythoside E: PKM2 Macrophage Workflow
2026-09-11
Forsythoside E connects PKM2 structural control with macrophage metabolic and inflammatory readouts, enabling more informative assays than cytokine measurements alone. This workflow shows how to test glycolytic remodeling, STAT3 signaling, M2 polarization, and translational relevance in sepsis-induced liver injury research.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-09-10
This ACS Nano study combines 99mTc-labeled nanoparticle SPECT/CT with primary liver-cell uptake assays to resolve how particle size and PEG chain length shape hepatic interactions. Its finding that hepatocytes and stellate cells can rival or exceed Kupffer-cell uptake provides a more nuanced framework for designing nanomedicines with reduced liver sequestration.
-
A-1331852: A Precision BCL-XL Inhibitor
2026-09-10
A-1331852 is a selective BCL-XL inhibitor for dissecting apoptotic dependence in cancer and senescence models. This article connects BH3-mimetic biology with practical assay design, emphasizing how cellular context, BAX/BAK status, and MCL1 compensation shape interpretation.
-
LG 101506: From RXR Biology to Translation
2026-09-09
A translational framework for using LG 101506 to investigate RXR signaling, metabolism regulation, and the RBMS1–B4GALT1–PD-L1 axis in immune-cold cancer models without overstating evidence.
-
GZMK+ CD8+ T Cells in Recurrent Airway Inflammation
2026-09-09
The reference study identifies persistent GZMK-expressing CD8+ effector-memory T-cell clones as drivers of recurrent nasal polyp and airway inflammation. By integrating T-cell receptor tracking, single-cell profiling, human tissue analysis, and mouse asthma experiments, it links GZMK proteolysis to complement activation and shows that targeting this pathway can reduce established disease.
-
Sulfo-Cy5 Carboxylic Acid: Imaging Guide
2026-09-08
Sulfo-Cy5 carboxylic acid is a water-compatible fluorescent dye for life sciences with supplier-reported excitation at 646 nm and emission at 662 nm. Its sulfonate groups support aqueous handling, while its non-activated carboxylic acid form means that protein and peptide labeling workflows should use an appropriate activation strategy or the pre-activated NHS ester variant.
-
Tacalcitol Induces NGF in Human Keratinocytes
2026-09-08
This 2001 study showed that tacalcitol, a synthetic analog of vitamin D3, induces nerve growth factor (NGF) production and NGF mRNA expression in human epidermal keratinocytes. Its time- and dose-dependent response provides a mechanistic basis for investigating vitamin D signaling in cutaneous nerve support, while remaining an in vitro result rather than evidence of clinical efficacy.
-
Rapamycin: Translational Logic for mTOR Inhibition
2026-09-07
Rapamycin (Sirolimus) is more than a potent mTOR pathway probe: it is a framework for testing how translational control, cell-cycle state, immune activation, and mitochondrial metabolism shape therapeutic response. This article connects product-level workflow decisions with evidence on 4E-BP1 regulation, rapamycin-resistant translation, lens epithelial cell biology, and a Leigh syndrome mitochondrial disease model.
-
One-step TUNEL Cy3 Apoptosis Detection Kit
2026-09-07
Translate drug-induced DNA fragmentation into spatially resolved evidence across CRC cell lines, organoids, and tissue sections. This workflow pairs terminal labeling with orthogonal viability and target-engagement measurements to distinguish apoptotic remodeling from nonspecific DNA damage.
-
Clasto-Lactacystin β-lactone in RIPK3 Assays
2026-09-05
Clasto-Lactacystin β-lactone provides a mechanistic way to test whether RIPK3 loss reflects proteasome-dependent degradation. This article translates viral immune-evasion findings into rigorous assay design, emphasizing temporal controls, orthogonal validation, and careful interpretation of cell death readouts.
-
Forsythoside E: PKM2 Immunometabolic Workflow
2026-09-04
Forsythoside E provides a mechanism-led workflow for studying PKM2 tetramerization, macrophage metabolism, and inflammatory liver injury. This guide translates its reported K311-dependent activity into practical cell, binding, metabolic, and mouse-model experiments with troubleshooting checkpoints.
-
Bifidobacterium vs FMT in Hepatic Encephalopathy
2026-09-04
This 2025 European Journal of Neuroscience study compared Bifidobacterium and fecal microbiota transplantation in bile duct ligation rats with chronic hepatic encephalopathy using [18F]PBR146 micro-PET/CT. The work shows that region-specific TSPO imaging may detect treatment-associated neuroinflammatory changes that are not apparent in global brain uptake, behavioral testing, or circulating cytokine measurements.